C4 Therapeutics (CCCC) Depreciation & Amortization (CF) (2019 - 2026)

C4 Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $404000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 11.4% year-over-year to $404000.0; the TTM figure through Mar 2026 stood at $1.9 million (up 4.44% YoY), while the FY2025 annual figure was $2.0 million, up 7.76% from the prior year.
• Depreciation & Amortization (CF) was $404000.0 for Q1 2026 at C4 Therapeutics, down from $428000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $615000.0 in Q2 2025 to a low of $300000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $452176.5 across 5 years, with a median of $448000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) sank 33.48% in 2022, then surged 66.67% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $521000.0 in 2022, then declined by 17.47% to $430000.0 in 2023, then gained by 11.63% to $480000.0 in 2024, then retreated by 10.83% to $428000.0 in 2025, then decreased by 5.61% to $404000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $404000.0 (Q1 2026), $428000.0 (Q4 2025), and $460000.0 (Q3 2025), per Business Quant data.